key: cord-0699490-f4iitmjd authors: Wang, X.; Gao, W.; Cui, S.; Zhang, Y.; Zheng, K.; Ke, J.; Lv, J.; Yu, C.; Sun, D.; Wang, Q.; Li, L. title: A population-based seroprevalence survey of severe acute respiratory syndrome coronavirus 2 infection in Beijing, China date: 2020-09-23 journal: nan DOI: 10.1101/2020.09.23.20197756 sha: 4624fdc3f3c733bd61d135745e3fffc2c4d2b7f1 doc_id: 699490 cord_uid: f4iitmjd BACKGOUND The spread of Coronavirus Disease 2019 (COVID-19) had been controlled in China. The seroprevalence of COVID-19 in Beijing has not been evaluated. METHODS In April, residents in Beijing were randomly enrolled. Blood samples were collected and antibodies to SARS-CoV-2 were tested by two colloidal gold kits. All colloidal gold positive serums were then tested by Micro-neutralization assay. RESULTS None of 2,184 residents participated was tested positive by micro-neutralization assay. The seroprevalence of COVID-19 in Beijing was estimated < 0.17%. CONCLUSIONS The seroprevalence of COVID-19 was low in April suggesting that community-wide spread was prevented in Beijing. Coronavirus Disease 2019 (COVID-19) has rapidly spread throughout the world. Reported cases only 40 represented a small fraction of the real number of cases, since most of asymptomatic cases were hardly 41 detected. According to a few early studies from Iceland, US and Iran, the seropositivity at community level 42 ranged from 0.6%-22%, much higher than the level of reported incidence rate [1] [2] [3] [4] . The rate of undetected 43 infections also varied in different countries. Investigating seroprevalence in different locations around the 44 world enables further understanding the infection spectrum, the incidence and case-fatality rate, and most 45 importantly, population immunity level of syndrome coronavirus 2 (SARS-CoV-2). Seroprevalence is also 46 a key factor to optimize strategies for disease prevention and control. Serological surveys enable the 47 determination of infection susceptibility, past acute infection and recovery group that has potentiality 48 immune to re-infection. Thus, it is essential to conduct a large-scale serological survey to SARS-CoV-2. Beijing -the political, cultural and international exchange center of China-faced an extraordinary challenge 51 both at home and abroad. The first COVID-19 case in Beijing was confirmed on January 19 th , 2020. The 52 authority in Beijing implemented a series control measures to prevent further spread during the past several 53 months. As of April 15, a total of 594 COVID-19 cases including 9 deaths were officially confirmed and 54 reported in Beijing, with an incidence rate of 2.75/100,000 and a case-fatality rate of 1.5%. To evaluate the effectiveness of control strategies and the risk of future epidemic in Beijing, a community-56 based serological survey was performed. 57 58 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in was defined as a group of people (1 or more) living in the same residence. All persons living in the household 75 had been invited to participate in the study, including children. If the age structure of samples were not 76 consistent with that of general population in targeted communities due to refusal or contraindication to 77 venipuncture, additional households were randomly selected to ensure the representativeness of samples. 78 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 23, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 138 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 23, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 23, 2020. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 23, 2020. 240 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 23, 2020. . https://doi.org/10.1101/2020.09.23.20197756 doi: medRxiv preprint Seroprevalence of COVID-19 virus infection in Guilan 222 province, Iran. medRxiv20079244v1 COVID-19 Antibody Seroprevalence Spread of SARS-CoV-2 in the Icelandic Population Seroprevalence of SARS-CoV-2-Specific Antibodies Among 230 World Health Organization. Population-based age-stratified seroepidemiological investigation 232 protocol for COVID-19 virus infection Evaluation of SARS-CoV-2 neutralizing antibodies using of 235 a CPE-based Colorimetric live virus micro-neutralization assay in human serum samples World Health Organization. Population-based age-stratified seroepidemiological investigation 238 Germany with direct contact to COVID-19 patients Prevalence of IgG antibodies to SARS-CoV-2 among emergency 246 department employees SARS-CoV-2 seroprevalence trends in healthy blood donors 248 during the COVID-19 Milan outbreak. medRxiv Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors -a pilot study of the value 251 of serology to determine population exposure. medRxiv Proportion of asymptomatic coronavirus disease 2019: A systematic 254 review and meta-analysis Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-257 2 in China Rapid point-of-care testing for SARS-CoV-2 in a community 259 screening setting shows low sensitivity